10X Genomics Inc（TXG）股票分析

$73.020

+1.497 (+2.05%)收盤時

Loading chart…

最高: 74.450
開盤: 70.810
成交量加權均價: 72.76
成交量: 1.40M
市值: 2.38B
最低: 70.810
成交金額: 102.22M
企業價值/稅息折舊攤銷前利潤（TTM）: -8.95

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

www.10xgenomics.com

估值指標

10X Genomics Inc（TXG）目前預期本益比為 -9.54，5 年平均預期本益比為 -45.79。

預期本益比

合理

5 年均值 P/E

-45.79

目前P/E

-9.54

高估

38.79

低估

-130.37

預期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-433.59

目前EV/EBITDA

-8.95

高估

1309.30

低估

-2176.47

預期股價營收比

合理

5 年均值 P/S

8.42

目前P/S

2.27

高估

14.63

低估

2.21

Alphio AI 對 TXG 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%TXG

$7.67

情境價格

基

基準

基準 · 50%TXG

$7.57

情境價格

悲

悲觀

悲觀 · 25%TXG

$6.64

情境價格

持有 TXG 的大戶

A

ARK Investment Management LLC

+ 持有TXG

+14.31%

3個月報酬率

H

Harvard Management Company, Inc.

+ 持有TXG

+9.53%

3個月報酬率

D

Davy Global Fund Management Limited

+ 持有TXG

+8.73%

3個月報酬率

H

Hillsdale Investment Management Inc.

+ 持有TXG

+7.06%

3個月報酬率

S

Sprott Inc.

+ 持有TXG

-0.63%

3個月報酬率

B

Baker Steel Capital Managers LLP

+ 持有TXG

-0.67%

3個月報酬率

事件時間軸

2026-10-07 (ET)

09:30:00

10x Genomics Partners with Fred Hutchinson Cancer Center for Multi-Project Research

2026-10-06 (ET)

12:30:00

10x Genomics Shares Drop 13.4% to $84.67

2026-09-29 (ET)

09:30:00

10x Genomics Announces First Commercial Shipments of Atera Platform

2026-09-24 (ET)

12:30:00

10x Genomics Stock Rises 7.6% to $81.33

2026-09-10 (ET)

09:30:00

10x Genomics Integrates Lunit's AI Pathology Platform

查看更多事件

資訊

查看更多資訊

TXG 常見問題 —— 由 Alphio AI 解答

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

社群

分享你對 TXG 的看法

basedbackdraft2026/9/15

$TXG -- did you buy? I did not.

0 0

註冊或登入後參與討論

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。